In this study of 500 patients with breast carcinoma, we have prospectively assessed the role of preoperative CA 15-3 as a marker of disea burden over a 7 year period. 
Breast cancer is the commonest malignancy in women. Up to 12% of women are diagnosed as having breast cancer, and 3.5% of women die from this disease. (Harris et al., 1992) . The presence and extent of lymph node involvement is currently the best established prognostic indicator. Other prognostic indicators include oestrogen and progesterone receptor status, tumour grade and growth rate, DNA ploidy and a variety of biochemical markers of tumour invasiveness and aggression.
Tumour markers have been widely appLied in diagnosis and long-term follow-up of cancer patients. Recent advances in monoclonal technology have led to the detection of tumour-specific monoclonal antibodis which have been marketed as potential tumour markers. These antibodies do not detect 'breast cancer-specific antigens', but instead they react with normal or modified tissue antigens which are either preferentially or inappropriately expressed on malignant cells. Many of these antigens are also detectable in the serum of patients with cancer.
The carinoma-associated antigen CA 15-3 is detectable in serum and is widely used as a tumour marker in patients with breast carcinoma. It is an antigen defined by two monoclonal antibodies, DF3 (raised against a membrane enriched fraction of a human breast carcinoma; Kufe et al., 1984) and 115D8 (raised aginst antigens of human milk fat globule membrane; Hilkens et al., 1984 Hilkens et al., , 1986 . It is detectable in the serum of breast cancer patients and has been shown to be relatively specific for breast carcinoma (Hayes et al., 1985) .
The exact role of monoclonal antibodies in the management of breast carcinoma has yet to be evahlated. Bloom and Richardson (1957) system. In addition, the presene of tumour invasion into blood vessels and lymphatics was noted, as was the extent of lymphocyte infiltration into the tumour.
CA 15-3 levels were measured using a commercially available immunoradiometric assay kit (CA 15-3 solid phase ELISA system, CIS Biointernational, ORIS Group, Gif-SurYvette, France). A sample of blood was obtained from the patent in the morning and serum was added to a test tube containing the antibody 115D8, coated on the enzyme-linked immunosorbent assay (ELISA) solid phase. This was then incubated at 3TC for 1 h. The tube was then aspirated and washed. Following this the tracer monodonal antibody, DF3, radiolabelled with iodine-125 was added. This was again incubated at 3rC for 1 h, followed by a further aspiration and washing. The level of bound radioactivity was measured using a gamma-camera and kvels of CA 15-3 were read from a standard curve. The coefficient of variation of the assay was ± 8%. The laboratory participates in the United Kingdom External Quality Asssment Scheme for Tumour Markers, and internal quality control specmens are run within each batch of analyses. The normal level of CA 15-3 is <30Uml-'.
Results were analysed using the Mann-Whitney U-test, the chi-square test, Fisher's exact test and regression analysis. Signif was asumed at the P <0.05 level. Values were analysed where applicable using two-tailed significance tests.
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A total of 500 patients with breast cancer were included in the study; 181 (36.2%) were premenopausal and 319 (63.8%) were post-menopausal. A total of 168 patients presented with (Table I) . CA 15-3 levels were significantly correlated with tumour size at presentation based on measurement of resected specimens (r = 0.364, P<0.005). There was a significant difference in CA 15-3 levels between Tl and T3 tumours (P< 0.005) as well as between TI and T4 tumours (P<0.005). The difference between TI and T2 tumours was not significant (P = 0.06) (Table II) .
There was a statistically significant positive correlation between CA 15-3 levels and the number of involved nodes in the group as a whole (r = 0.362, P<0.005) and the number of involved nodes in patients in whom ten or more nodes were examined (r = 0.497, P <0.005). A significant difference in CA 15-3 levels was found between NO and Nl tumours (P<0.005) and NO and N2 tumours (P<0.005). There was no significant difference between Nl and N2 tumours (P= 0.06) (Table II) .
There was a significant difference between TINOMO tumours and TlNIMO tumours (P=0.006) as well as between TINOMO tumours and T2NIMO tumours (P= 0.01). There was no significant difference between TINOMO and T2NOMO (P = 0.2), T2NOMO and T2NlMO (P = 0.3) or TINIMO and T2NIMO tumours (P=0.3).
CA 15-3 levels were highest in patients presenting with metastatic disease. There was a significant difference in levels between patients with metastatic disease and those without metastatic disease at presentation (P<0.005) (Table II) .
Histopathological characteristics of the tumours were examined. There was no significant difference in CA 15-3 levels between patients with ductal carcinoma and patients with other types of carcinoma. The percentage of patients with an elevated CA 15-3 was increased in medullary carcinoma but this failed to reach statistical significance (Table  III) .
Tumour grade or oestrogen receptor status (positive or negative) did not affect the CA 15-3 level (Table III) . There was no correlation between CA 15-3 levels and oestrogen receptor levels (r = 0.0003; P = NS). In addition. CA 15-3 levels were not related to the presence of lymphatic or venous invasion (Table III) . However, CA 15-3 levels were related to the extent of lymphocyte infiltration, which was reported on in 61 cases. This could be divided into none, moderate or florid, and patients with florid lymphocyte infiltration had significantly elevated CA 15-3 levels (Table III) .
A patient presenting with a CA 15-3 > 50 U ml-' had a 91% chance of having advanced i.e. stage III or stage IV disease (Table IV) .
There was a fall in levels of CA Gion et al. (1991) . This study has failed to demonstrate that CA 15-3 has prognostic significance at presentation in early disease, however it does provide information on tumour burden as patients with levels of greater than 40 U ml-' have an 83% chance of having at least stage III disease. We recommend the routine use of this valuable tumour marker in the preoperative assessment of patients who present with primary breast carcinoma.
